RxDoctor Payments Data

Dustin Raber, MD

Family Medicine · Hanford, CANPI 1962413625

Payments from drug & device makers

$1,524in general payments, 2019–2025

Across 120 payments — averaging $12.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$390
  • AstraZeneca$226
  • Novo Nordisk$142
  • Amgen$81
  • Johnson & Johnson$81
  • Amarin Pharma, Inc.$79
  • plus $527 from 17 others

What the payments were for

  • Food & beverage$1,518100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,524 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$461,378
Medicare patients
560
Services billed
16,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban638$168,487
OzempicSemaglutide59$65,001
MounjaroTirzepatide54$55,426
JardianceEmpagliflozin95$44,130
JanuviaSitagliptin Phosphate32$35,788
MyrbetriqMirabegron95$32,893
Tresiba Flextouch U-200Insulin Degludec12$21,192
Lantus SolostarInsulin Glargine,hum.Rec.Anlog160$15,292
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog81$15,107
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen633$12,505
LokelmaSodium Zirconium Cyclosilicate76$11,010
Gabapentin992$10,545
Atorvastatin Calcium1,269$9,722
Levothyroxine Sodium1,220$9,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$51$171,524663 claims
Novo NordiskOzempic$142$65,00159 claims
Lilly USA, LLCMounjaro$49$55,42654 claims
Boehringer IngelheimJardiance$42$44,13095 claims
MerckJanuvia, Janumet Xr$35$42,73543 claims
Astellas Pharma US IncMyrbetriq$43$32,89395 claims
GSKTrelegy Ellipta, Arexvy$34$12,61227 claims
AstraZenecaLokelma$226$11,01076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Hanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →